A Study of TAK-981 in Participants With Relapsed/Refractory Solid Tumors or Non-Hodgkin Lymphoma (NHL)
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study is in 2 parts.
The main aims of the 1st part of the study are to check if people with advanced solid tumors
or cancers in the immune system (lymphomas) have side effects from TAK-981, and to check how
much TAK-981 they can receive without getting side effects from it.
The main aims of the 2nd part of the study are to learn if the condition of people with
specific cancers improves after treatment with TAK-981. Another aim is to check for side
effects from TAK-981.
In the 1st part of the study, participants will receive TAK-981. In the 2nd part of the
study, participants with specific tumor types will receive TAK-981 at the recommended phase 2
dose determined during the 1st part of the study.
In both parts of the study, participants can receive TAK-981 for up to 1 year or longer if
their condition stays improved.